There are currently no FDA-approved treatments for CIAS, a disabling feature of the disease that includes impaired attention, memory, and executive function. The Food and Drug Administration (FDA) has ...

PALI-2108 is the first and only PDE4 inhibitor in development designed for targeted delivery to the terminal ileum and colon, addressing ...

– ALTO-101 has been shown to positively impact cognition and key cognition-related EEG markers in humans when delivered orally – – Novel transdermal formulation of ALTO-101 exhibited favorable ...

PALI-2108 is the first and only PDE4 inhibitor in development targetingthe terminal ileum and colon for treatment of ulcerative colitis (UC) and ...

Martin Kolb, MD, PhD, discusses the challenges of treating idiopathic pulmonary fibrosis (IPF) and highlights the potential benefits of a new PDE4B inhibitor, nerandomilast. Idiopathic pulmonary ...

Researchers from Southern Medical University have divulged the discovery and preclinical characterization of novel PDE4 inhibitors for the treatment of hepatic sepsis. Synthesis and optimization of a ...

Phosphodiesterase 4 (PDE4) is an enzyme known to play a role in inflammatory responses, and it has been pinpointed as an interesting therapeutic target for diseases like atopic dermatitis (AD), but ...

Advances ongoing development of PALI-2108 across fibrostenotic Crohn’s disease and ulcerative colitis, with Phase 2 IND submission planned for H1 2026 Carlsbad, CA, Oct. 20, 2025 (GLOBE NEWSWIRE) -- ...

Announcing a new publication for Acta Materia Medica journal. Phosphodiesterase-4 (PDE4), a member of the phosphodiesterase superfamily, has highly important roles in cyclic nucleotide signaling ...